Clinical trial · Observational
Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina
NCT01861236CI-TRIAL-00035418FAST ARcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective, observational study to collect and analyze data on patients with advanced hormone dependent prostate cancer treated with Firmagon® according to routine medical practice in Argentina
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Hormone Dependent Prostate Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Firmagon® (degarelix) | Drug | Degarelix | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Advanced Prostate Cancer
- description
- Advanced Prostate Cancer that receive Firmagon therapy in the context of usual clinical practice
- interventionNames
- Drug: Firmagon® (degarelix)
Primary outcomes (1)
- measure
- Progression-free survival (PFS) failure rate (with failure defined as either prostate-specific antigen (PSA) failure, introduction of additional therapy related to prostate cancer, or death)
- timeFrame
- During 3 years treatment
- description
- The PFS failure rate will be estimated with time to PFS failure as dependent and adjusting for disease stage at baseline, baseline PSA, baseline testosterone (if available) and baseline serum Alkaline Phosphatase (s-ALP, if available)
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Advanced Prostate Cancer patients to be treated with Firmagon in the context of usual clinical practice * Written informed consent Exclusion Criteria: * Contraindications to Firmagon * Patients already on Firmagon therapy
References
Publications (0)
Data not yet available
No reference posted for this study.